SCHEMBL2669476

SCHEMBL2669476

C=Cc1cc(F)ccc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 6/20 0.47
AR P10275 1/20 0.43
PTGS1 P23219 1/20 0.42
ERN1 O75460 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
RELA Q04206 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP1A1 P04798 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP1B1 Q16678 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TRPA1 O75762 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31280415 0.84 MDM2 (0.43) NFE2L2PTGS1ERN1CYP1A2CYP1A1
SCHEMBL17163861 0.84 MDM2 (0.43) NFE2L2PTGS1ERN1CYP1A2CYP1A1
SCHEMBL273404 0.80 ERN1 (0.56) NFE2L2ARERN1LMNAMAPK1
SCHEMBL29432755 0.80 ERN1 (0.56) NFE2L2ARERN1LMNAMAPK1
SCHEMBL16955823 0.80 NFE2L2 (0.47) NFE2L2ARPTGS1ERN1LMNA
SCHEMBL16950428 0.79 L3MBTL1 (0.45) LMNARAB9ACYP1A2ALDH1A1CYP2C19
SCHEMBL339513 0.79 ALDH1A1 (0.43) ARLMNAHTTALDH1A1
SCHEMBL13925800 0.78 HMGCR (0.57) NFE2L2ARPTGS1MAPK1RELA
SCHEMBL24716965 0.78 NFE2L2 (0.49) NFE2L2PTGS1ERN1CYP1A2CYP1A1
SCHEMBL1792533 0.78 CYP1A1 (0.61) NFE2L2RAB9ACYP1A2CYP1A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4707264-A2 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS Verbio SE (DE) 2026-03-11 EP disclosed
EP-4122924-B1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2025-11-19 EP disclosed
US-12065450-B2 Compounds and the use thereof in metathesis reactions VERBIO SE (DE) 2024-08-20 US disclosed
EP-4122924-A2 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS Verbio Vereinigte BioEnergie AG (DE) 2023-01-25 EP disclosed
US-20230013959-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2023-01-19 US disclosed
US-11414446-B1 Compounds and the use thereof in metathesis reactions VERBIO VEREINIGTE BIOENERGIE AG 2022-08-16 US disclosed
EP-3129365-B1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO VER BIOENERGIE AG (DE) 2022-05-04 EP disclosed
CN-106471005-B Compounds and their use in metathesis reactions 沃比奥联合生物能源公司 2020-04-24 CN disclosed
US-20190119311-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO VEREINIGTE BIOENERGIE AG (DE) 2019-04-25 US disclosed
US-10106566-B2 Compounds and the use thereof in metathesis reactions XIMO AG (CH) 2018-10-23 US disclosed
EP-3129365-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS XiMo AG (CH) 2017-02-15 EP disclosed
US-20170037069-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2017-02-09 US disclosed
WO-2015155593-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS XIMO AG (CH) 2015-10-15 WO disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
WO-2010093535-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119311-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS PRMT6, CYP2D6, POR NFE2L2 867/4885AR 606/4885PTGS1 1728/4885
US-11414446-B1 Compounds and the use thereof in metathesis reactions PRMT6, CYP2D6, POR NFE2L2 867/4885AR 606/4885PTGS1 1728/4885
US-12065450-B2 Compounds and the use thereof in metathesis reactions PRMT6, CYP2D6, POR NFE2L2 867/4885AR 606/4885PTGS1 1728/4885
US-10106566-B2 Compounds and the use thereof in metathesis reactions CYP2D6, PRMT6, POR NFE2L2 660/4885AR 662/4885PTGS1 1620/4885
US-20230013959-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS PRMT6, CYP2D6, POR NFE2L2 867/4885AR 606/4885PTGS1 1728/4885
US-20170037069-A1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS CYP2D6, PRMT6, POR NFE2L2 660/4885AR 662/4885PTGS1 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.